| GlaxoSmithKline AG - Fluarix Tetra 15 µg / 0.5 ml, Injektionssuspension | | 62961 | | 06 | | Fluarix Tetra 15 µg / 0.5 ml | | Injektionssuspension | | J07BB02 | | Influenza, Inactivated, Split Virus Or Surface Antigen | | 08.08.2019 | | |
| | Composition | | haemagglutininum influenzae A (H1N1) (Virus Stamm A/Brisbane/02/2018 (H1N1)-like: reassortant virus IVR-190 derived from A/Brisbane/02/2018) 15 µg, haemagglutininum influenzae A (H3N2) (Virus Stamm A/Kansas/14/2017 (H3N2)-like: reassortant virus NYMC X-327 derived from A/Kansas/14/0217) 15 µg, haemagglutininum influenzae B (Virus Stamm B/Colorado/06/2017-like: reassortant virus B/Maryland/15/2016 NYMC BX-69A (Victoria lineage)) 15 µg, haemagglutininum influenzae B (Virus Stamm B/Phuket/3073/2013 (Yamagata lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alpha-tocopheroli hydrogenosuccinas, residui: ovalbuminum max. 0.05 µg, formaldehydum max. 5 µg, natrii desoxycholas max. 65 µg, gentamicini sulfas nihil, hydrocortisonum nihil, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml. | | Packungsbestandteile | | Injection suspension | | | | | | Active Agent | Dose |
|---|
| | 15 µg | | | 15 µg | | | 15 µg |
| | | | Inactive agents | Dose | additional_information |
|---|
| | | | | Disodium Phosphate Dodecahydrate | | | | Formaldehydum | 5 µg | | | | | | | | 15 µg | | | | | | | Potassium Chloride | | | | Potassium Dihydrogenophosphate | | | | Magnesium Chloride Hexahydrate | | | | Sodium Chloride | | | | | 65 µg | | | | | | | | 0.05 µg | residui | | Polysorbatum 80 | | |
|
| | Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| No entries have been found. |
|
|
